Evidence map›Paper›PMID 24624328›Full record

ArticleNeuroImage. Clinical2014

Application of quantitative DTI metrics in sporadic CJD.

E Caverzasi, R G Henry, P Vitali, I V Lobach, J Kornak, S Bastianello, S J Dearmond, B L Miller, H J Rosen, M L Mandelli and 1 more

Open access · goldAbstract read
In one paragraph

Article in NeuroImage. Clinical, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. PRNP expression predicts imaging findings in sporadic Creutzfeldt-Jakob disease.Annals of clinical and translational neurology · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Selective vulnerability to atrophy in sporadic Creutzfeldt-Jakob disease.Annals of clinical and translational neurology · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Prion Diseases.Neurologic clinics · 2018
    Review
  13. Neuroimaging in Dementia.Seminars in neurology · 2017
    Review
  14. Article
  15. Article
  16. Advanced magnetic resonance imaging of neurodegenerative diseases.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017
    Review
  17. Clinical radiological correlation in E200K familial Creutzfeldt-Jakob disease.Journal of neural transmission (Vienna, Austria : 1996) · 2016
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

E CaverzasiDepartment of Neurology, University of California, San Francisco (UCSF), San Francisco, CA, USA ; Department of Neuroradiology, C. Mondino National Neurological Institute, Pavia. University of Pavia, Italy.
R G HenryDepartment of Neurology, University of California, San Francisco (UCSF), San Francisco, CA, USA ; Graduate Group in Bioengineering, UCSF, San Francisco, CA, USA ; Department of Radiology and Biomedical Imaging, UCSF, San Francisco, CA, USA.
P VitaliBrain MRI 3T Mondino Research Center C. Mondino National Neurological Institute, Pavia, Italy.
I V LobachDepartment of Neurology, University of California, San Francisco (UCSF), San Francisco, CA, USA.
J KornakDepartment of Epidemiology and Biostatistics, UCSF, San Francisco, CA, USA.
S BastianelloDepartment of Neuroradiology, C. Mondino National Neurological Institute, Pavia. University of Pavia, Italy.
S J DearmondInstitute for Neurodegenerative Diseases, University of California, San Francisco (UCSF), USA ; Department of Pathology, University of California, San Francisco (UCSF), USA.
B L MillerMemory and Aging Center, Department of Neurology, University of California, San Francisco, (UCSF), USA.
H J RosenMemory and Aging Center, Department of Neurology, University of California, San Francisco, (UCSF), USA.
M L MandelliMemory and Aging Center, Department of Neurology, University of California, San Francisco, (UCSF), USA.
M D GeschwindMemory and Aging Center, Department of Neurology, University of California, San Francisco, (UCSF), USA.
University of California, San Francisco · USFondazione Istituto Neurologico Nazionale Casimiro Mondino · ITUniversity of Pavia · IT

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
UNDERSTANDING AND IMPROVING SMALL MOLECULE INHIBITORS OF PRION REPLICATIONP01AG021601 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRUSINER, STANLEY B · 2003 to 2013
$31.9M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Towards Therapeutics for Neurodegenerative DiseasesR37AG031220 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRUSINER, STANLEY B · 2008 to 2017
$6.2M
Predicting progression of human prion diseaseR01AG031189 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESCHWIND, MICHAEL D · 2008 to 2017
$5.7M
New Clinical Approaches to Creutzfeldt-Jakob DiseaseK23AG021989 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESCHWIND, MICHAEL D · 2003 to 2007
$602k
NCRR NIH HHS UL1 RR024131NIA NIH HHS K23 AG021989NIA NIH HHS P01 AG021601NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG031189NIA NIH HHS R37 AG031220
6 · The paper itself

Abstract

Diffusion Weighted Imaging is extremely important for the diagnosis of probable sporadic Jakob-Creutzfeldt disease, the most common human prion disease. Although visual assessment of DWI MRI is critical diagnostically, a more objective, quantifiable approach might more precisely identify the precise pattern of brain involvement. Furthermore, a quantitative, systematic tracking of MRI changes occurring over time might provide insights regarding the underlying histopathological mechanisms of human prion disease and provide information useful for clinical trials. The purposes of this study were: 1) to describe quantitatively the average cross-sectional pattern of reduced mean diffusivity, fractional anisotropy, atrophy and T1 relaxation in the gray matter (GM) in sporadic Jakob-Creutzfeldt disease, 2) to study changes in mean diffusivity and atrophy over time and 3) to explore their relationship with clinical scales. Twenty-six sporadic Jakob-Creutzfeldt disease and nine control subjects had MRIs on the same scanner; seven sCJD subjects had a second scan after approximately two months. Cortical and subcortical gray matter regions were parcellated with Freesurfer. Average cortical thickness (or subcortical volume), T1-relaxiation and mean diffusivity from co-registered diffusion maps were calculated in each region for each subject. Quantitatively on cross-sectional analysis, certain brain regions were preferentially affected by reduced mean diffusivity (parietal, temporal lobes, posterior cingulate, thalamus and deep nuclei), but with relative sparing of the frontal and occipital lobes. Serial imaging, surprisingly showed that mean diffusivity did not have a linear or unidirectional reduction over time, but tended to decrease initially and then reverse and increase towards normalization. Furthermore, there was a strong correlation between worsening of patient clinical function (based on modified Barthel score) and increasing mean diffusivity.

Indexed as

AgingAlgorithmsBrainCreutzfeldt-Jakob SyndromeDiffusion Tensor ImagingFemaleGray MatterHumansImage Interpretation, Computer-AssistedMaleMiddle AgedReproducibility of ResultsSensitivity and SpecificityAtrophyCreutzfeldt–Jakob diseaseDWIMDPrion diseasesCJD

Identifiers

PMID24624328
PMCPMC3950558
OpenAlexW2086112283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.